Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma

The co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a potential target for immune checkpoint inhibition immunotherapies. However, little is known about the biological and clinical significance of LAG3 DNA methylation in melanoma and its microenvironment. We evaluated LAG3 promoter a...

Full description

Saved in:
Bibliographic Details
Published inEBioMedicine Vol. 59; p. 102962
Main Authors Fröhlich, Anne, Sirokay, Judith, Fietz, Simon, Vogt, Timo J., Dietrich, Jörn, Zarbl, Romina, Florin, Mike, Kuster, Pia, Saavedra, Gonzalo, Valladolid, Susana Ramírez, Hoffmann, Friederike, Flatz, Lukas, Ring, Sandra S., Golletz, Carsten, Pietsch, Torsten, Strieth, Sebastian, Brossart, Peter, Gielen, Gerrit H., Kristiansen, Glen, Bootz, Friedrich, Landsberg, Jennifer, Dietrich, Dimo
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.09.2020
Elsevier
Subjects
DNA Methylation
Immunotherapy
LAG3
Melanoma
Predictive Biomarker
Research paper
Predictive Biomarker
LAG3
DNA Methylation
Immunotherapy
Melanoma
Online AccessGet full text

Cover

Abstract The co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a potential target for immune checkpoint inhibition immunotherapies. However, little is known about the biological and clinical significance of LAG3 DNA methylation in melanoma and its microenvironment. We evaluated LAG3 promoter and gene body methylation in a cohort of N = 470 melanoma patients obtained from The Cancer Genome Atlas (TCGA cohort), an independent cohort of N = 120 patients from the University Hospital Bonn, and in subsets of peripheral blood leukocytes, melanocytes, and melanoma cell lines. We validated the association of LAG3 methylation with mRNA expression in vitro in the melanoma cell line A375 treated with the hypomethylating agent 5-azacytidine and stimulated with interferon-γ. Finally, we investigated correlations between LAG3 methylation and progression-free survival in patients treated with immune checkpoint blockade (ICB cohort, N = 118). Depending on the analysed locus (promoter, gene body) we found region-dependent significant LAG3 methylation differences between monocytes, B cells, CD8+ and CD4+ T cells, regulatory T cells, melanocytes, and melanoma cell lines. In tumor tissues, methylation correlated significantly with LAG3 mRNA expression, immune cell infiltrates (histopathologic lymphocyte score and RNA-Seq signatures of distinct immune infiltrates), and an interferon-γ signature. Finally, LAG3 methylation was associated with overall survival in the TCGA cohort and progression-free survival in the ICB cohort. We detected basal LAG3 mRNA expression in the melanoma cell A375 and an interferon-γ inducible expression after demethylation with 5-azacytidine. Our study points towards an epigenetic regulation of LAG3 via promoter methylation and suggests a prognostic and predictive significance of LAG3 methylation in melanoma. Our results give insight in the tumor cell-intrinsic transcriptional regulation of LAG3 in melanoma. In perspective, our results might pave the way for investigating LAG3 methylation as a predictive biomarker for response to anti-LAG3 immune checkpoint blockage. A full list of funding bodies that contributed to this study can be found in the Acknowledgements section.
AbstractList The co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a potential target for immune checkpoint inhibition immunotherapies. However, little is known about the biological and clinical significance of LAG3 DNA methylation in melanoma and its microenvironment. We evaluated LAG3 promoter and gene body methylation in a cohort of N = 470 melanoma patients obtained from The Cancer Genome Atlas (TCGA cohort), an independent cohort of N = 120 patients from the University Hospital Bonn, and in subsets of peripheral blood leukocytes, melanocytes, and melanoma cell lines. We validated the association of LAG3 methylation with mRNA expression in vitro in the melanoma cell line A375 treated with the hypomethylating agent 5-azacytidine and stimulated with interferon-γ. Finally, we investigated correlations between LAG3 methylation and progression-free survival in patients treated with immune checkpoint blockade (ICB cohort, N = 118). Depending on the analysed locus (promoter, gene body) we found region-dependent significant LAG3 methylation differences between monocytes, B cells, CD8 and CD4 T cells, regulatory T cells, melanocytes, and melanoma cell lines. In tumor tissues, methylation correlated significantly with LAG3 mRNA expression, immune cell infiltrates (histopathologic lymphocyte score and RNA-Seq signatures of distinct immune infiltrates), and an interferon-γ signature. Finally, LAG3 methylation was associated with overall survival in the TCGA cohort and progression-free survival in the ICB cohort. We detected basal LAG3 mRNA expression in the melanoma cell A375 and an interferon-γ inducible expression after demethylation with 5-azacytidine. Our study points towards an epigenetic regulation of LAG3 via promoter methylation and suggests a prognostic and predictive significance of LAG3 methylation in melanoma. Our results give insight in the tumor cell-intrinsic transcriptional regulation of LAG3 in melanoma. In perspective, our results might pave the way for investigating LAG3 methylation as a predictive biomarker for response to anti-LAG3 immune checkpoint blockage. A full list of funding bodies that contributed to this study can be found in the Acknowledgements section.
Background: The co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a potential target for immune checkpoint inhibition immunotherapies. However, little is known about the biological and clinical significance of LAG3 DNA methylation in melanoma and its microenvironment. Methods: We evaluated LAG3 promoter and gene body methylation in a cohort of N = 470 melanoma patients obtained from The Cancer Genome Atlas (TCGA cohort), an independent cohort of N = 120 patients from the University Hospital Bonn, and in subsets of peripheral blood leukocytes, melanocytes, and melanoma cell lines. We validated the association of LAG3 methylation with mRNA expression in vitro in the melanoma cell line A375 treated with the hypomethylating agent 5-azacytidine and stimulated with interferon-γ. Finally, we investigated correlations between LAG3 methylation and progression-free survival in patients treated with immune checkpoint blockade (ICB cohort, N = 118). Findings: Depending on the analysed locus (promoter, gene body) we found region-dependent significant LAG3 methylation differences between monocytes, B cells, CD8+ and CD4+ T cells, regulatory T cells, melanocytes, and melanoma cell lines. In tumor tissues, methylation correlated significantly with LAG3 mRNA expression, immune cell infiltrates (histopathologic lymphocyte score and RNA-Seq signatures of distinct immune infiltrates), and an interferon-γ signature. Finally, LAG3 methylation was associated with overall survival in the TCGA cohort and progression-free survival in the ICB cohort. We detected basal LAG3 mRNA expression in the melanoma cell A375 and an interferon-γ inducible expression after demethylation with 5-azacytidine. Interpretation: Our study points towards an epigenetic regulation of LAG3 via promoter methylation and suggests a prognostic and predictive significance of LAG3 methylation in melanoma. Our results give insight in the tumor cell-intrinsic transcriptional regulation of LAG3 in melanoma. In perspective, our results might pave the way for investigating LAG3 methylation as a predictive biomarker for response to anti-LAG3 immune checkpoint blockage. Funding: A full list of funding bodies that contributed to this study can be found in the Acknowledgements section.
The co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a potential target for immune checkpoint inhibition immunotherapies. However, little is known about the biological and clinical significance of LAG3 DNA methylation in melanoma and its microenvironment. We evaluated LAG3 promoter and gene body methylation in a cohort of N = 470 melanoma patients obtained from The Cancer Genome Atlas (TCGA cohort), an independent cohort of N = 120 patients from the University Hospital Bonn, and in subsets of peripheral blood leukocytes, melanocytes, and melanoma cell lines. We validated the association of LAG3 methylation with mRNA expression in vitro in the melanoma cell line A375 treated with the hypomethylating agent 5-azacytidine and stimulated with interferon-γ. Finally, we investigated correlations between LAG3 methylation and progression-free survival in patients treated with immune checkpoint blockade (ICB cohort, N = 118). Depending on the analysed locus (promoter, gene body) we found region-dependent significant LAG3 methylation differences between monocytes, B cells, CD8+ and CD4+ T cells, regulatory T cells, melanocytes, and melanoma cell lines. In tumor tissues, methylation correlated significantly with LAG3 mRNA expression, immune cell infiltrates (histopathologic lymphocyte score and RNA-Seq signatures of distinct immune infiltrates), and an interferon-γ signature. Finally, LAG3 methylation was associated with overall survival in the TCGA cohort and progression-free survival in the ICB cohort. We detected basal LAG3 mRNA expression in the melanoma cell A375 and an interferon-γ inducible expression after demethylation with 5-azacytidine. Our study points towards an epigenetic regulation of LAG3 via promoter methylation and suggests a prognostic and predictive significance of LAG3 methylation in melanoma. Our results give insight in the tumor cell-intrinsic transcriptional regulation of LAG3 in melanoma. In perspective, our results might pave the way for investigating LAG3 methylation as a predictive biomarker for response to anti-LAG3 immune checkpoint blockage. A full list of funding bodies that contributed to this study can be found in the Acknowledgements section.
BACKGROUNDThe co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a potential target for immune checkpoint inhibition immunotherapies. However, little is known about the biological and clinical significance of LAG3 DNA methylation in melanoma and its microenvironment. METHODSWe evaluated LAG3 promoter and gene body methylation in a cohort of N = 470 melanoma patients obtained from The Cancer Genome Atlas (TCGA cohort), an independent cohort of N = 120 patients from the University Hospital Bonn, and in subsets of peripheral blood leukocytes, melanocytes, and melanoma cell lines. We validated the association of LAG3 methylation with mRNA expression in vitro in the melanoma cell line A375 treated with the hypomethylating agent 5-azacytidine and stimulated with interferon-γ. Finally, we investigated correlations between LAG3 methylation and progression-free survival in patients treated with immune checkpoint blockade (ICB cohort, N = 118). FINDINGSDepending on the analysed locus (promoter, gene body) we found region-dependent significant LAG3 methylation differences between monocytes, B cells, CD8+ and CD4+ T cells, regulatory T cells, melanocytes, and melanoma cell lines. In tumor tissues, methylation correlated significantly with LAG3 mRNA expression, immune cell infiltrates (histopathologic lymphocyte score and RNA-Seq signatures of distinct immune infiltrates), and an interferon-γ signature. Finally, LAG3 methylation was associated with overall survival in the TCGA cohort and progression-free survival in the ICB cohort. We detected basal LAG3 mRNA expression in the melanoma cell A375 and an interferon-γ inducible expression after demethylation with 5-azacytidine. INTERPRETATIONOur study points towards an epigenetic regulation of LAG3 via promoter methylation and suggests a prognostic and predictive significance of LAG3 methylation in melanoma. Our results give insight in the tumor cell-intrinsic transcriptional regulation of LAG3 in melanoma. In perspective, our results might pave the way for investigating LAG3 methylation as a predictive biomarker for response to anti-LAG3 immune checkpoint blockage. FUNDINGA full list of funding bodies that contributed to this study can be found in the Acknowledgements section.
ArticleNumber 102962
Author Saavedra, Gonzalo
Fröhlich, Anne
Gielen, Gerrit H.
Fietz, Simon
Kuster, Pia
Kristiansen, Glen
Ring, Sandra S.
Dietrich, Jörn
Dietrich, Dimo
Landsberg, Jennifer
Golletz, Carsten
Bootz, Friedrich
Valladolid, Susana Ramírez
Strieth, Sebastian
Sirokay, Judith
Flatz, Lukas
Vogt, Timo J.
Hoffmann, Friederike
Brossart, Peter
Florin, Mike
Zarbl, Romina
Pietsch, Torsten
Author_xml – sequence: 1
  givenname: Anne
  surname: Fröhlich
  fullname: Fröhlich, Anne
  organization: Department of Dermatology and Allergy, University of Bonn, Bonn, Germany
– sequence: 2
  givenname: Judith
  surname: Sirokay
  fullname: Sirokay, Judith
  organization: Department of Dermatology and Allergy, University of Bonn, Bonn, Germany
– sequence: 3
  givenname: Simon
  orcidid: 0000-0003-3745-9125
  surname: Fietz
  fullname: Fietz, Simon
  organization: Department of Dermatology and Allergy, University of Bonn, Bonn, Germany
– sequence: 4
  givenname: Timo J.
  surname: Vogt
  fullname: Vogt, Timo J.
  organization: Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany
– sequence: 5
  givenname: Jörn
  surname: Dietrich
  fullname: Dietrich, Jörn
  organization: Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany
– sequence: 6
  givenname: Romina
  surname: Zarbl
  fullname: Zarbl, Romina
  organization: Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany
– sequence: 7
  givenname: Mike
  surname: Florin
  fullname: Florin, Mike
  organization: Department of Dermatology and Allergy, University of Bonn, Bonn, Germany
– sequence: 8
  givenname: Pia
  surname: Kuster
  fullname: Kuster, Pia
  organization: Department of Dermatology and Allergy, University of Bonn, Bonn, Germany
– sequence: 9
  givenname: Gonzalo
  surname: Saavedra
  fullname: Saavedra, Gonzalo
  organization: Department of Dermatology and Allergy, University of Bonn, Bonn, Germany
– sequence: 10
  givenname: Susana Ramírez
  surname: Valladolid
  fullname: Valladolid, Susana Ramírez
  organization: Department of Dermatology and Allergy, University of Bonn, Bonn, Germany
– sequence: 11
  givenname: Friederike
  surname: Hoffmann
  fullname: Hoffmann, Friederike
  organization: Department of Dermatology and Allergy, University of Bonn, Bonn, Germany
– sequence: 12
  givenname: Lukas
  surname: Flatz
  fullname: Flatz, Lukas
  organization: Institute of Immunobiology, Kantonsspital St Gallen, St Gallen, Switzerland
– sequence: 13
  givenname: Sandra S.
  surname: Ring
  fullname: Ring, Sandra S.
  organization: Institute of Immunobiology, Kantonsspital St Gallen, St Gallen, Switzerland
– sequence: 14
  givenname: Carsten
  surname: Golletz
  fullname: Golletz, Carsten
  organization: Institute of Pathology, University Hospital Bonn, Bonn, Germany
– sequence: 15
  givenname: Torsten
  surname: Pietsch
  fullname: Pietsch, Torsten
  organization: Institute of Neuropathology, University Hospital Bonn, Bonn, Germany
– sequence: 16
  givenname: Sebastian
  surname: Strieth
  fullname: Strieth, Sebastian
  organization: Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany
– sequence: 17
  givenname: Peter
  surname: Brossart
  fullname: Brossart, Peter
  organization: Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany
– sequence: 18
  givenname: Gerrit H.
  orcidid: 0000-0002-2707-0290
  surname: Gielen
  fullname: Gielen, Gerrit H.
  organization: Institute of Neuropathology, University Hospital Bonn, Bonn, Germany
– sequence: 19
  givenname: Glen
  surname: Kristiansen
  fullname: Kristiansen, Glen
  organization: Institute of Pathology, University Hospital Bonn, Bonn, Germany
– sequence: 20
  givenname: Friedrich
  surname: Bootz
  fullname: Bootz, Friedrich
  organization: Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany
– sequence: 21
  givenname: Jennifer
  surname: Landsberg
  fullname: Landsberg, Jennifer
  organization: Department of Dermatology and Allergy, University of Bonn, Bonn, Germany
– sequence: 22
  givenname: Dimo
  surname: Dietrich
  fullname: Dietrich, Dimo
  email: dimo.dietrich@gmail.com
  organization: Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32861198$$D View this record in MEDLINE/PubMed
BookMark eNp9kU9vEzEQxVeoiJbST4CEfOTQBP_37gGkqECpFOACZ8trjxNHXjt4dyv12-M0pWovnGzPvPmN9d7r5iTlBE3zluAlwUR-2C2hD3lYUkwPFdpJ-qI5o0zQBeskP3lyP20uxnGHMSaC12L7qjlltJWEdO1Z03_PEewcTblENoYUbN6baZtj3gRr4iUyyaEwDHMCZHMpEM0EI8oerVfXDO1LHvIEBX3-sUIDTNu72g85oZDqM5qUB_OmeelNHOHi4Txvfn_98uvq22L98_rmarVeWEHFtPAOpFAGuCCKMAy8E60SLeGst5Q5wp3vHaZUYJA9F7zHwgkCwlopFXaCnTc3R67LZqf3JQym3Olsgr4v5LLRpkzBRtCAnSdeOe-V5461HbbetZb00ikO3YH16cjaz_0AzkKaionPoM87KWz1Jt9qxZUghFTA-wdAyX9mGCc9hNFCrJZAnkdNOWul6gjtqpQdpbbkcSzgH9cQrA9h652-D1sfwtbHsOvUu6c_fJz5F20VfDwKoHp-G6Do0QZIFlwoYKdqSvjvgr_RC75y
CitedBy_id crossref_primary_10_1016_j_ejr_2023_01_004
crossref_primary_10_1016_j_semcancer_2021_03_012
crossref_primary_10_3389_fimmu_2021_622563
crossref_primary_10_2217_epi_2020_0208
crossref_primary_10_19053_01217488_v14_n2_2023_15041
crossref_primary_10_1186_s12935_023_03157_5
crossref_primary_10_1038_s41416_023_02292_0
crossref_primary_10_1097_CM9_0000000000001981
crossref_primary_10_3390_jpm11090901
crossref_primary_10_1016_j_ebiom_2020_103005
crossref_primary_10_1007_s00262_020_02777_4
crossref_primary_10_1158_1078_0432_CCR_21_2390
crossref_primary_10_3389_fimmu_2022_868786
crossref_primary_10_1016_j_jare_2021_11_016
crossref_primary_10_3389_fimmu_2021_795121
crossref_primary_10_1007_s11060_021_03721_x
crossref_primary_10_3389_fimmu_2024_1329775
crossref_primary_10_3389_fimmu_2020_615317
crossref_primary_10_3389_fimmu_2021_785091
crossref_primary_10_1155_2022_8114731
crossref_primary_10_1007_s00105_022_05078_2
crossref_primary_10_1080_2162402X_2021_1926762
crossref_primary_10_1186_s13148_022_01270_2
crossref_primary_10_2147_IJGM_S335713
crossref_primary_10_1038_s42003_021_02361_1
crossref_primary_10_1186_s12891_021_04472_6
crossref_primary_10_4049_jimmunol_2100850
Cites_doi 10.1002/eji.1830241246
10.1016/j.cell.2015.05.044
10.3389/fonc.2019.01040
10.1016/j.canlet.2005.04.015
10.1038/nbt.2203
10.1007/7651_2015_260
10.1038/sj.emboj.7601520
10.1111/pcmr.12745
10.1002/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A
10.3389/fmed.2019.00027
10.4049/jimmunol.0804211
10.1038/jid.2014.29
10.1136/jitc-2020-000552
10.1080/2162402X.2016.1221555
10.1038/nm1093
10.1093/annonc/mdx557
10.1038/s41590-018-0217-9
10.1016/j.cell.2018.11.010
10.1080/2162402X.2016.1239005
10.1093/nar/gkx1098
10.18632/oncotarget.17354
10.1093/hmg/ddt420
10.1080/15592294.2015.1084462
10.3389/fimmu.2019.00453
10.1186/1471-2105-12-323
10.1016/j.ebiom.2020.102647
10.1172/JCI31184
10.7150/jca.25187
10.1158/1078-0432.CCR-14-2926
10.1038/ncomms13507
10.1158/1078-0432.CCR-13-3271
10.1080/2162402X.2017.1288329
10.1080/2162402X.2016.1257454
10.1084/jem.171.5.1393
10.1016/j.celrep.2018.03.086
10.1158/1078-0432.CCR-15-1849
10.4049/jimmunol.1002050
10.4049/jimmunol.1301395
10.1186/1471-2105-11-587
10.1038/nrc.2016.36
10.1186/s40425-019-0737-3
10.1186/s12916-017-0851-3
10.1016/j.cell.2009.06.001
10.18632/oncotarget.13161
10.1080/2162402X.2017.1356144
10.1016/j.cell.2017.06.007
10.1038/leu.2016.328
10.1038/nmeth.3337
10.1038/srep13351
10.1111/imr.12519
10.1016/j.ebiom.2018.01.016
10.4049/jimmunol.169.10.5392
10.4049/jimmunol.0800185
10.2217/epi-2018-0149
10.1158/2326-6066.CIR-14-0150
10.1111/cas.12986
10.1016/j.immuni.2018.03.023
10.1016/j.trecan.2017.11.005
10.1371/journal.pgen.1003678
10.1002/cam4.1700
10.3390/cancers11081213
10.1093/intimm/dxp107
10.1007/s00262-015-1696-2
10.1158/0008-5472.CAN-11-1620
10.1158/0008-5472.CAN-13-2690
10.3233/CBM-181278
10.1038/bjc.2014.416
10.1016/j.immuni.2004.08.010
10.1111/pcmr.12757
10.1186/s13148-017-0354-2
10.4049/jimmunol.0903879
10.4049/jimmunol.172.9.5450
10.1371/journal.pone.0109080
10.1371/journal.pone.0104484
10.7554/eLife.44310
10.1007/s00432-018-2620-x
10.1172/JCI91190
10.4049/jimmunol.1401025
10.1016/j.jtho.2017.01.019
10.1172/jci.insight.96793
10.4161/epi.6.5.15335
10.1016/j.immuni.2016.10.022
10.1038/s41416-018-0220-9
10.1080/2162402X.2018.1542918
10.1186/s13148-018-0512-1
10.1038/s41598-019-47382-3
ContentType Journal Article
Copyright 2020 The Author(s)
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
2020 The Author(s) 2020
Copyright_xml – notice: 2020 The Author(s)
– notice: Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
– notice: 2020 The Author(s) 2020
DBID 6I.
AAFTH
NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1016/j.ebiom.2020.102962
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2352-3964
EndPage 102962
ExternalDocumentID oai_doaj_org_article_e0df1f7dff7f4d3890cfd8c1b6d74e95
10_1016_j_ebiom_2020_102962
32861198
S2352396420303388
Genre Journal Article
GrantInformation A full list of funding bodies that contributed to this study can be found in the Acknowledgements section.
GroupedDBID .1-
.FO
0R~
0SF
4.4
457
53G
5VS
6I.
AACTN
AAEDT
AAEDW
AAFTH
AAIKJ
AALRI
AAXUO
ABMAC
ACGFS
ADBBV
ADEZE
ADRAZ
AEXQZ
AFCTW
AFRHN
AFTJW
AGHFR
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AOIJS
BCNDV
EBS
EJD
FDB
GROUPED_DOAJ
HYE
HZ~
IPNFZ
KQ8
M41
M48
NCXOZ
O9-
OK1
RIG
ROL
RPM
SSZ
Z5R
AAMRU
ADVLN
AKRWK
NPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c525t-fde657ae4517130e4958758143bc23d14dfbd02250e6b454b05d51e5cc6670d53
IEDL.DBID RPM
ISSN 2352-3964
IngestDate Tue Oct 22 15:08:26 EDT 2024
Tue Sep 17 21:10:17 EDT 2024
Fri Oct 25 10:16:02 EDT 2024
Thu Sep 26 16:14:16 EDT 2024
Sat Sep 28 08:27:10 EDT 2024
Tue Jul 25 20:58:01 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Predictive Biomarker
LAG3
DNA Methylation
Immunotherapy
Melanoma
Language English
License This is an open access article under the CC BY license.
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c525t-fde657ae4517130e4958758143bc23d14dfbd02250e6b454b05d51e5cc6670d53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors are joint senior authors on this work.
These authors are joint first authors on this work.
ORCID 0000-0003-3745-9125
0000-0002-2707-0290
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475111/
PMID 32861198
PQID 2438679129
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_e0df1f7dff7f4d3890cfd8c1b6d74e95
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7475111
proquest_miscellaneous_2438679129
crossref_primary_10_1016_j_ebiom_2020_102962
pubmed_primary_32861198
elsevier_sciencedirect_doi_10_1016_j_ebiom_2020_102962
PublicationCentury 2000
PublicationDate 2020-09-01
PublicationDateYYYYMMDD 2020-09-01
PublicationDate_xml – month: 09
  year: 2020
  text: 2020-09-01
  day: 01
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle EBioMedicine
PublicationTitleAlternate EBioMedicine
PublicationYear 2020
Publisher Elsevier B.V
Elsevier
Publisher_xml – name: Elsevier B.V
– name: Elsevier
References Taube, Klein, Brahmer (bib0081) 2014; 20
Kong, Wang, Song (bib0082) 2019; 10
(bib0049) 2015; 161
Li, Dewey (bib0063) 2011; 12
Zhang, Cardarelli, Carroll (bib0085) 2011; 6
Lingohr, Dohmen, Semaan (bib0042) 2019; 11
Camisaschi, Casati, Rini (bib0008) 2010; 184
Gevensleben, Holmes, Goltz (bib0037) 2016; 7
Becker, De Bastiani, Parisi (bib0068) 2015; 5
Newman, Liu, Green (bib0053) 2015; 12
Goltz, Gevensleben, Dietrich (bib0039) 2017; 8
Xiong, Wang, You (bib0071) 2019; 9
Wu, Zhang, Xing (bib0074) 2014; 111
Guo, Zhu, Zhu, Chen, Wang, Chen (bib0055) 2019; 8
Workman, Dugger, Vignali (bib0002) 2002; 169
Workman, Wang, El Kasmi (bib0004) 2009; 182
Woo, Turnis, Goldberg (bib0010) 2012; 72
He, Yu, Rozeboom (bib0025) 2017; 12
Fumet, Richard, Ledys (bib0080) 2018; 119
Ghoneim, Fan, Moustaki (bib0032) 2017; 170
Yu, Yang, Jiao, Li, Zhang, Wang (bib0084) 2015; 64
Couzin-Frankel (bib0001) 2013; 342
Ventham, Kennedy, Adams (bib0060) 2016; 7
Khair, Bax, Mele (bib0065) 2019; 10
Fröhlich, Loick, Bawden (bib0047) 2020; 52
Marwitz, Scheufele, Perner, Reck, Ammerpohl, Goldmann (bib0034) 2017; 9
Durham, Nirschl, Jackson (bib0012) 2014; 9
Hemon, Jean-Louis, Ramgolam (bib0029) 2011; 186
Absher, Li, Waite (bib0058) 2013; 9
Richter, Agnellini, Oxenius (bib0067) 2010; 22
Kouo, Huang, Pucsek (bib0018) 2015; 3
Triebel, Jitsukawa, Baixeras (bib0048) 1990; 171
Deng, Mao, Yu (bib0023) 2016; 5
Goltz, Gevensleben, Vogt (bib0035) 2018; 3
Zerbino, Achuthan, Akanni (bib0089) 2018; 46
Grosso, Goldberg, Getnet (bib0014) 2009; 182
Saleh, Peinado, Fuentes-Antrás (bib0030) 2019; 9
Li, Wang, Forbes (bib0086) 2007; 26
Zarour (bib0011) 2016; 22
Giraldo, Becht, Pagès (bib0024) 2015; 21
Durek, Nordström, Gasparoni (bib0031) 2016; 45
Andrews, Marciscano, Drake, Vignali (bib0006) 2017; 276
Workman, Rice, Dugger, Kurschner, Vignali (bib0005) 2002; 32
Huard, Tournier, Hercend, Triebel, Faure (bib0015) 1994; 24
Klümper, Ralser, Bawden (bib0009) 2020; 8
Xu, Liu, Liu (bib0019) 2014; 74
Wouters, Vizoso, Martinez-Cardus (bib0057) 2017; 15
Jha, Workman, McGaha (bib0020) 2014; 9
Rogala, Glück, Mazur (bib0016) 2002; 12
Bae, Lee, Park, Lee, Chun (bib0021) 2014; 193
Goltz, Gevensleben, Dietrich (bib0038) 2016; 5
Du, Zhang, Huang (bib0061) 2010; 11
Wang, Sanmamed, Datar (bib0003) 2019; 176
Li, Jilisihan, Wang, Tang, Keyoumu (bib0027) 2018; 23
Xing, Guo, Ding (bib0083) 2017; 7
Curiel, Coukos, Zou (bib0078) 2004; 10
Goltz, Gevensleben, Dietrich, Dietrich (bib0040) 2016; 6
Micevic, Thakral, McGeary, Bosenberg (bib0043) 2019; 32
Marzese, Scolyer, Huynh (bib0056) 2014; 23
Lee, Jun, Lee (bib0026) 2018; 144
Thorsson, Gibbs, Brown (bib0052) 2018; 48
Němejcová, Tichá, Bártů (bib0054) 2019; 32
Nair, El Salhat, Taha, John, Ali, Elkord (bib0046) 2018; 10
Solinas, Migliori, De Silva, Willard-Gallo (bib0075) 2019 Aug 20; 11
Kümpers, Jokic, Haase (bib0072) 2019; 6
Carter, Cibulskis, Helman (bib0050) 2012; 30
Topalian, Taube, Anders, Pardoll (bib0073) 2016; 16
Phillips, Corces (bib0066) 2009; 137
Prendergast, Mondal, Dey, Laury-Kleintop, Muller (bib0079) 2018; 4
Burugu, Gao, Leung, Chia, Nielsen (bib0022) 2017; 28
Jung, Uhl, Kristiansen, Dietrich (bib0062) 2017; 1589
Maruhashi, Okazaki, Sugiura (bib0076) 2018; 19
Mamrut, Avidan, Staun-Ram (bib0059) 2015; 10
Ayers, Lunceford, Nebozhyn (bib0088) 2017; 127
He, Rivard, Rozeboom (bib0064) 2016; 107
Grosso, Kelleher, Harris (bib0013) 2007; 117
Chen, Zhang, Wang (bib0036) 2017; 6
Scharer, Barwick, Youngblood, Ahmed, Boss (bib0033) 2013; 191
Camisaschi, De Filippo, Beretta (bib0069) 2014; 134
Triebel, Hacene, Pichon (bib0028) 2006; 235
Huang, Workman, Flies (bib0007) 2004; 21
Goltz, Gevensleben, Grünen (bib0041) 2017; 31
Workman, Cauley, Kim, Blackman, Woodland, Vignali (bib0017) 2004; 172
Röver, Gevensleben, Dietrich (bib0044) 2018; 28
Wang, Burger, Taube (bib0070) 2019; 11
Ni, Lu (bib0077) 2018; 7
Saltz, Gupta, Hou (bib0051) 2018; 23
Elashi, Sasidharan Nair, Taha, Shaath, Elkord (bib0045) 2018; 8
Wu, Chen, Wang (bib0087) 2019; 7
Durham (10.1016/j.ebiom.2020.102962_bib0012) 2014; 9
Durek (10.1016/j.ebiom.2020.102962_bib0031) 2016; 45
Workman (10.1016/j.ebiom.2020.102962_bib0002) 2002; 169
Marzese (10.1016/j.ebiom.2020.102962_bib0056) 2014; 23
Khair (10.1016/j.ebiom.2020.102962_bib0065) 2019; 10
Curiel (10.1016/j.ebiom.2020.102962_bib0078) 2004; 10
Camisaschi (10.1016/j.ebiom.2020.102962_bib0008) 2010; 184
Wouters (10.1016/j.ebiom.2020.102962_bib0057) 2017; 15
Micevic (10.1016/j.ebiom.2020.102962_bib0043) 2019; 32
Giraldo (10.1016/j.ebiom.2020.102962_bib0024) 2015; 21
Guo (10.1016/j.ebiom.2020.102962_bib0055) 2019; 8
Carter (10.1016/j.ebiom.2020.102962_bib0050) 2012; 30
Newman (10.1016/j.ebiom.2020.102962_bib0053) 2015; 12
Němejcová (10.1016/j.ebiom.2020.102962_bib0054) 2019; 32
He (10.1016/j.ebiom.2020.102962_bib0064) 2016; 107
Becker (10.1016/j.ebiom.2020.102962_bib0068) 2015; 5
Workman (10.1016/j.ebiom.2020.102962_bib0004) 2009; 182
Klümper (10.1016/j.ebiom.2020.102962_bib0009) 2020; 8
Deng (10.1016/j.ebiom.2020.102962_bib0023) 2016; 5
Saleh (10.1016/j.ebiom.2020.102962_bib0030) 2019; 9
Saltz (10.1016/j.ebiom.2020.102962_bib0051) 2018; 23
Elashi (10.1016/j.ebiom.2020.102962_bib0045) 2018; 8
Wang (10.1016/j.ebiom.2020.102962_bib0003) 2019; 176
Lee (10.1016/j.ebiom.2020.102962_bib0026) 2018; 144
Chen (10.1016/j.ebiom.2020.102962_bib0036) 2017; 6
Yu (10.1016/j.ebiom.2020.102962_bib0084) 2015; 64
Wu (10.1016/j.ebiom.2020.102962_bib0087) 2019; 7
Goltz (10.1016/j.ebiom.2020.102962_bib0040) 2016; 6
Workman (10.1016/j.ebiom.2020.102962_bib0005) 2002; 32
Woo (10.1016/j.ebiom.2020.102962_bib0010) 2012; 72
Goltz (10.1016/j.ebiom.2020.102962_bib0035) 2018; 3
Scharer (10.1016/j.ebiom.2020.102962_bib0033) 2013; 191
Triebel (10.1016/j.ebiom.2020.102962_bib0048) 1990; 171
(10.1016/j.ebiom.2020.102962_bib0049) 2015; 161
Jung (10.1016/j.ebiom.2020.102962_bib0062) 2017; 1589
Taube (10.1016/j.ebiom.2020.102962_bib0081) 2014; 20
Ayers (10.1016/j.ebiom.2020.102962_bib0088) 2017; 127
Rogala (10.1016/j.ebiom.2020.102962_bib0016) 2002; 12
Lingohr (10.1016/j.ebiom.2020.102962_bib0042) 2019; 11
Workman (10.1016/j.ebiom.2020.102962_bib0017) 2004; 172
Grosso (10.1016/j.ebiom.2020.102962_bib0014) 2009; 182
Absher (10.1016/j.ebiom.2020.102962_bib0058) 2013; 9
Xing (10.1016/j.ebiom.2020.102962_bib0083) 2017; 7
Richter (10.1016/j.ebiom.2020.102962_bib0067) 2010; 22
Wu (10.1016/j.ebiom.2020.102962_bib0074) 2014; 111
Fröhlich (10.1016/j.ebiom.2020.102962_bib0047) 2020; 52
Bae (10.1016/j.ebiom.2020.102962_bib0021) 2014; 193
Goltz (10.1016/j.ebiom.2020.102962_bib0038) 2016; 5
Li (10.1016/j.ebiom.2020.102962_bib0086) 2007; 26
Xiong (10.1016/j.ebiom.2020.102962_bib0071) 2019; 9
Zhang (10.1016/j.ebiom.2020.102962_bib0085) 2011; 6
Huard (10.1016/j.ebiom.2020.102962_bib0015) 1994; 24
He (10.1016/j.ebiom.2020.102962_bib0025) 2017; 12
Ventham (10.1016/j.ebiom.2020.102962_bib0060) 2016; 7
Grosso (10.1016/j.ebiom.2020.102962_bib0013) 2007; 117
Mamrut (10.1016/j.ebiom.2020.102962_bib0059) 2015; 10
Huang (10.1016/j.ebiom.2020.102962_bib0007) 2004; 21
Du (10.1016/j.ebiom.2020.102962_bib0061) 2010; 11
Phillips (10.1016/j.ebiom.2020.102962_bib0066) 2009; 137
Burugu (10.1016/j.ebiom.2020.102962_bib0022) 2017; 28
Goltz (10.1016/j.ebiom.2020.102962_bib0041) 2017; 31
Couzin-Frankel (10.1016/j.ebiom.2020.102962_bib0001) 2013; 342
Gevensleben (10.1016/j.ebiom.2020.102962_bib0037) 2016; 7
Triebel (10.1016/j.ebiom.2020.102962_bib0028) 2006; 235
Fumet (10.1016/j.ebiom.2020.102962_bib0080) 2018; 119
Kong (10.1016/j.ebiom.2020.102962_bib0082) 2019; 10
Kümpers (10.1016/j.ebiom.2020.102962_bib0072) 2019; 6
Nair (10.1016/j.ebiom.2020.102962_bib0046) 2018; 10
Thorsson (10.1016/j.ebiom.2020.102962_bib0052) 2018; 48
Camisaschi (10.1016/j.ebiom.2020.102962_bib0069) 2014; 134
Prendergast (10.1016/j.ebiom.2020.102962_bib0079) 2018; 4
Andrews (10.1016/j.ebiom.2020.102962_bib0006) 2017; 276
Li (10.1016/j.ebiom.2020.102962_bib0027) 2018; 23
Jha (10.1016/j.ebiom.2020.102962_bib0020) 2014; 9
Ghoneim (10.1016/j.ebiom.2020.102962_bib0032) 2017; 170
Marwitz (10.1016/j.ebiom.2020.102962_bib0034) 2017; 9
Wang (10.1016/j.ebiom.2020.102962_bib0070) 2019; 11
Zarour (10.1016/j.ebiom.2020.102962_bib0011) 2016; 22
Solinas (10.1016/j.ebiom.2020.102962_bib0075) 2019; 11
Xu (10.1016/j.ebiom.2020.102962_bib0019) 2014; 74
Goltz (10.1016/j.ebiom.2020.102962_bib0039) 2017; 8
Kouo (10.1016/j.ebiom.2020.102962_bib0018) 2015; 3
Hemon (10.1016/j.ebiom.2020.102962_bib0029) 2011; 186
Zerbino (10.1016/j.ebiom.2020.102962_bib0089) 2018; 46
Maruhashi (10.1016/j.ebiom.2020.102962_bib0076) 2018; 19
Röver (10.1016/j.ebiom.2020.102962_bib0044) 2018; 28
Topalian (10.1016/j.ebiom.2020.102962_bib0073) 2016; 16
Ni (10.1016/j.ebiom.2020.102962_bib0077) 2018; 7
Li (10.1016/j.ebiom.2020.102962_bib0063) 2011; 12
References_xml – volume: 5
  year: 2016
  ident: bib0023
  article-title: LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
  publication-title: Oncoimmunology
  contributor:
    fullname: Yu
– volume: 30
  start-page: 413
  year: 2012
  end-page: 421
  ident: bib0050
  article-title: Absolute quantification of somatic DNA alterations in human cancer
  publication-title: Nat Biotechnol
  contributor:
    fullname: Helman
– volume: 10
  start-page: 78
  year: 2018
  ident: bib0046
  article-title: DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
  publication-title: Clin Epigenetics
  contributor:
    fullname: Elkord
– volume: 9
  year: 2014
  ident: bib0012
  article-title: Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo
  publication-title: PLoS One
  contributor:
    fullname: Jackson
– volume: 22
  start-page: 13
  year: 2010
  end-page: 23
  ident: bib0067
  article-title: On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection
  publication-title: Int Immunol
  contributor:
    fullname: Oxenius
– volume: 10
  start-page: 942
  year: 2004
  end-page: 949
  ident: bib0078
  article-title: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
  publication-title: Nat Med
  contributor:
    fullname: Zou
– volume: 32
  start-page: 2255
  year: 2002
  end-page: 2263
  ident: bib0005
  article-title: Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)
  publication-title: Eur J Immunol.
  contributor:
    fullname: Vignali
– volume: 193
  start-page: 3101
  year: 2014
  end-page: 3112
  ident: bib0021
  article-title: Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling
  publication-title: J Immunol
  contributor:
    fullname: Chun
– volume: 6
  start-page: 27
  year: 2019
  ident: bib0072
  article-title: Immune cell infiltration of the primary tumor, Not PD-L1 status, is associated with improved response to checkpoint inhibition in metastatic melanoma
  publication-title: Front Med (Lausanne)
  contributor:
    fullname: Haase
– volume: 19
  start-page: 1415
  year: 2018
  end-page: 1426
  ident: bib0076
  article-title: LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
  publication-title: Nat Immunol
  contributor:
    fullname: Sugiura
– volume: 191
  start-page: 3419
  year: 2013
  end-page: 3429
  ident: bib0033
  article-title: Global DNA methylation remodeling accompanies CD8 T cell effector function
  publication-title: J Immunol
  contributor:
    fullname: Boss
– volume: 12
  start-page: 453
  year: 2015
  end-page: 457
  ident: bib0053
  article-title: Robust enumeration of cell subsets from tissue expression profiles
  publication-title: Nat Methods
  contributor:
    fullname: Green
– volume: 10
  start-page: 943
  year: 2015
  end-page: 957
  ident: bib0059
  article-title: Integrative analysis of methylome and transcriptome in human blood identifies extensive sex- and immune cell-specific differentially methylated regions
  publication-title: Epigenetics
  contributor:
    fullname: Staun-Ram
– volume: 28
  start-page: 2977
  year: 2017
  end-page: 2984
  ident: bib0022
  article-title: LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors
  publication-title: Ann Oncol
  contributor:
    fullname: Nielsen
– volume: 23
  start-page: 226
  year: 2014
  end-page: 238
  ident: bib0056
  article-title: Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis
  publication-title: Hum Mol Genet
  contributor:
    fullname: Huynh
– volume: 111
  start-page: 1391
  year: 2014
  end-page: 1399
  ident: bib0074
  article-title: PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients
  publication-title: Br J Cancer
  contributor:
    fullname: Xing
– volume: 11
  start-page: 1213
  year: 2019 Aug 20
  ident: bib0075
  article-title: LAG3: the biological processes that motivate targeting this immune checkpoint molecule in human cancer
  publication-title: Cancers (Basel)
  contributor:
    fullname: Willard-Gallo
– volume: 11
  start-page: e6352
  year: 2019
  ident: bib0070
  article-title: PD-L1, PD-1, LAG-3, and TIM-3 in melanoma: expression in brain metastases compared to corresponding extracranial tumors
  publication-title: Cureus
  contributor:
    fullname: Taube
– volume: 26
  start-page: 494
  year: 2007
  end-page: 504
  ident: bib0086
  article-title: Metalloproteases regulate T-cell proliferation and effector function via LAG-3
  publication-title: EMBO J
  contributor:
    fullname: Forbes
– volume: 182
  start-page: 1885
  year: 2009
  end-page: 1891
  ident: bib0004
  article-title: LAG-3 regulates plasmacytoid dendritic cell homeostasis
  publication-title: J Immunol
  contributor:
    fullname: El Kasmi
– volume: 7
  start-page: 79943
  year: 2016
  end-page: 79955
  ident: bib0037
  article-title: PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
  publication-title: Oncotarget
  contributor:
    fullname: Goltz
– volume: 21
  start-page: 3031
  year: 2015
  end-page: 3040
  ident: bib0024
  article-title: Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer
  publication-title: Clin Cancer Res
  contributor:
    fullname: Pagès
– volume: 31
  start-page: 738
  year: 2017
  end-page: 743
  ident: bib0041
  article-title: PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia
  publication-title: Leukemia
  contributor:
    fullname: Grünen
– volume: 4
  start-page: 38
  year: 2018
  end-page: 58
  ident: bib0079
  article-title: Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive ‘Cold’ Tumors ‘Hot’
  publication-title: Trends Cancer
  contributor:
    fullname: Muller
– volume: 52
  start-page: 102647
  year: 2020
  ident: bib0047
  article-title: Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma
  publication-title: EBioMedicine
  contributor:
    fullname: Bawden
– volume: 6
  start-page: 623
  year: 2011
  end-page: 629
  ident: bib0085
  article-title: Significant differences in global genomic DNA methylation by gender and race/ethnicity in peripheral blood
  publication-title: Epigenetics
  contributor:
    fullname: Carroll
– volume: 64
  start-page: 853
  year: 2015
  end-page: 860
  ident: bib0084
  article-title: Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis
  publication-title: Cancer Immunol Immunother
  contributor:
    fullname: Wang
– volume: 12
  start-page: 198
  year: 2002
  end-page: 203
  ident: bib0016
  article-title: Do the molecules CD26 and lymphocytes activation gene-3 differentiate between type 1 and 2 T cell response?
  publication-title: J Investig Allergol Clin Immunol.
  contributor:
    fullname: Mazur
– volume: 176
  start-page: 334
  year: 2019
  end-page: 347.e12
  ident: bib0003
  article-title: Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3
  publication-title: Cell
  contributor:
    fullname: Datar
– volume: 7
  year: 2017
  ident: bib0083
  article-title: Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients
  publication-title: Oncoimmunology
  contributor:
    fullname: Ding
– volume: 184
  start-page: 6545
  year: 2010
  end-page: 6551
  ident: bib0008
  article-title: LAG-3 Expression Defines a Subset of CD4
  publication-title: J Immunol
  contributor:
    fullname: Rini
– volume: 127
  start-page: 2930
  year: 2017
  end-page: 2940
  ident: bib0088
  article-title: IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
  publication-title: J Clin Invest
  contributor:
    fullname: Nebozhyn
– volume: 48
  start-page: 812
  year: 2018
  end-page: 830.e14
  ident: bib0052
  article-title: The immune landscape of cancer
  publication-title: Immunity
  contributor:
    fullname: Brown
– volume: 235
  start-page: 147
  year: 2006
  end-page: 153
  ident: bib0028
  article-title: A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors
  publication-title: Cancer Lett
  contributor:
    fullname: Pichon
– volume: 171
  start-page: 1393
  year: 1990
  end-page: 1405
  ident: bib0048
  article-title: LAG-3, a novel lymphocyte activation gene closely related to CD4
  publication-title: J Exp Med
  contributor:
    fullname: Baixeras
– volume: 8
  year: 2018
  ident: bib0045
  article-title: DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients
  publication-title: Oncoimmunology
  contributor:
    fullname: Elkord
– volume: 172
  start-page: 5450
  year: 2004
  end-page: 5455
  ident: bib0017
  article-title: Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo
  publication-title: J Immunol
  contributor:
    fullname: Vignali
– volume: 32
  start-page: 435
  year: 2019
  end-page: 440
  ident: bib0043
  article-title: PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival
  publication-title: Pigment Cell Melanoma Res
  contributor:
    fullname: Bosenberg
– volume: 9
  year: 2013
  ident: bib0058
  article-title: Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations
  publication-title: PLoS Genet
  contributor:
    fullname: Waite
– volume: 186
  start-page: 5173
  year: 2011
  end-page: 5183
  ident: bib0029
  article-title: MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis
  publication-title: J Immunol
  contributor:
    fullname: Ramgolam
– volume: 6
  year: 2017
  ident: bib0036
  article-title: The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications
  publication-title: Oncoimmunology
  contributor:
    fullname: Wang
– volume: 8
  start-page: 41011
  year: 2017
  end-page: 41020
  ident: bib0039
  article-title: PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients
  publication-title: Oncotarget
  contributor:
    fullname: Dietrich
– volume: 32
  start-page: 412
  year: 2019
  end-page: 423
  ident: bib0054
  article-title: Comparison of five different scoring methods in the evaluation of inflammatory infiltration (tumor-infiltrating lymphocytes) in superficial spreading and nodular melanoma
  publication-title: Pigment Cell Melanoma Res
  contributor:
    fullname: Bártů
– volume: 28
  start-page: 97
  year: 2018
  end-page: 104
  ident: bib0044
  article-title: PD-1 (PDCD1) promoter methylation is a prognostic factor in patients with diffuse lower-grade gliomas harboring isocitrate dehydrogenase (IDH) mutations
  publication-title: EBioMedicine
  contributor:
    fullname: Dietrich
– volume: 24
  start-page: 3216
  year: 1994
  end-page: 3221
  ident: bib0015
  article-title: Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes
  publication-title: Eur J Immunol
  contributor:
    fullname: Faure
– volume: 10
  start-page: 1745
  year: 2019
  end-page: 1754
  ident: bib0082
  article-title: Circulating lymphocytes, PD-L1 expression on tumor-infiltrating lymphocytes, and survival of colorectal cancer patients with different mismatch repair gene status
  publication-title: J Cancer
  contributor:
    fullname: Song
– volume: 9
  start-page: 51
  year: 2017
  ident: bib0034
  article-title: Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
  publication-title: Clin Epigenetics
  contributor:
    fullname: Goldmann
– volume: 46
  start-page: D754
  year: 2018
  end-page: D761
  ident: bib0089
  article-title: Ensembl 2018
  publication-title: Nucleic Acids Res
  contributor:
    fullname: Akanni
– volume: 170
  start-page: 142
  year: 2017
  end-page: 157.e19
  ident: bib0032
  article-title: De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation
  publication-title: Cell
  contributor:
    fullname: Moustaki
– volume: 10
  start-page: 453
  year: 2019
  ident: bib0065
  article-title: Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma
  publication-title: Front Immunol
  contributor:
    fullname: Mele
– volume: 23
  start-page: 181
  year: 2018
  end-page: 193.e7
  ident: bib0051
  article-title: Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images
  publication-title: Cell Rep
  contributor:
    fullname: Hou
– volume: 20
  start-page: 5064
  year: 2014
  end-page: 5074
  ident: bib0081
  article-title: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
  publication-title: Clin Cancer Res
  contributor:
    fullname: Brahmer
– volume: 276
  start-page: 80
  year: 2017
  end-page: 96
  ident: bib0006
  article-title: LAG3 (CD223) as a cancer immunotherapy target
  publication-title: Immunol Rev
  contributor:
    fullname: Vignali
– volume: 6
  year: 2016
  ident: bib0040
  article-title: PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients
  publication-title: Oncoimmunology
  contributor:
    fullname: Dietrich
– volume: 161
  start-page: 1681
  year: 2015
  end-page: 1696
  ident: bib0049
  article-title: Genomic Classification of Cutaneous Melanoma
  publication-title: Cell
– volume: 119
  start-page: 950
  year: 2018
  end-page: 960
  ident: bib0080
  article-title: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
  publication-title: Br J Cancer
  contributor:
    fullname: Ledys
– volume: 7
  start-page: 264
  year: 2019
  ident: bib0087
  article-title: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
  publication-title: J Immunother Cancer
  contributor:
    fullname: Wang
– volume: 21
  start-page: 503
  year: 2004
  end-page: 513
  ident: bib0007
  article-title: Role of LAG-3 in regulatory T cells
  publication-title: Immunity
  contributor:
    fullname: Flies
– volume: 9
  start-page: 1040
  year: 2019
  ident: bib0030
  article-title: Prognostic value of lymphocyte-activation Gene 3 (LAG3) in cancer: a meta-analysis
  publication-title: Front Oncol
  contributor:
    fullname: Fuentes-Antrás
– volume: 5
  start-page: 13351
  year: 2015
  ident: bib0068
  article-title: Integrated transcriptomics establish macrophage polarization signatures and have potential applications for clinical health and disease
  publication-title: Sci Rep
  contributor:
    fullname: Parisi
– volume: 137
  start-page: 1194
  year: 2009
  end-page: 1211
  ident: bib0066
  article-title: CTCF: master weaver of the genome
  publication-title: Cell
  contributor:
    fullname: Corces
– volume: 182
  start-page: 6659
  year: 2009
  end-page: 6669
  ident: bib0014
  article-title: Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells
  publication-title: J Immunol
  contributor:
    fullname: Getnet
– volume: 107
  start-page: 1193
  year: 2016
  end-page: 1197
  ident: bib0064
  article-title: Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
  publication-title: Cancer Sci
  contributor:
    fullname: Rozeboom
– volume: 144
  start-page: 1005
  year: 2018
  end-page: 1014
  ident: bib0026
  article-title: CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer
  publication-title: J Cancer Res Clin Oncol
  contributor:
    fullname: Lee
– volume: 12
  start-page: 323
  year: 2011
  ident: bib0063
  article-title: RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
  publication-title: BMC Bioinformatics
  contributor:
    fullname: Dewey
– volume: 134
  start-page: 1893
  year: 2014
  end-page: 1902
  ident: bib0069
  article-title: Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3
  publication-title: J Invest Dermatol
  contributor:
    fullname: Beretta
– volume: 117
  start-page: 3383
  year: 2007
  end-page: 3392
  ident: bib0013
  article-title: LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems
  publication-title: J Clin Invest
  contributor:
    fullname: Harris
– volume: 9
  year: 2014
  ident: bib0020
  article-title: Lymphocyte activation Gene-3 (LAG-3) negatively regulates environmentally-induced autoimmunity
  publication-title: PLoS One
  contributor:
    fullname: McGaha
– volume: 16
  start-page: 275
  year: 2016
  end-page: 287
  ident: bib0073
  article-title: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
  publication-title: Nat Rev Cancer
  contributor:
    fullname: Pardoll
– volume: 3
  start-page: 412
  year: 2015
  end-page: 423
  ident: bib0018
  article-title: Galectin-3 shapes antitumor immune responses by suppressing CD8+ T Cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells
  publication-title: Cancer Immunol Res
  contributor:
    fullname: Pucsek
– volume: 22
  start-page: 1856
  year: 2016
  end-page: 1864
  ident: bib0011
  article-title: Reversing T-cell dysfunction and exhaustion in cancer
  publication-title: Clin Cancer Res
  contributor:
    fullname: Zarour
– volume: 11
  start-page: 587
  year: 2010
  ident: bib0061
  article-title: Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis
  publication-title: BMC Bioinf
  contributor:
    fullname: Huang
– volume: 1589
  start-page: 139
  year: 2017
  end-page: 159
  ident: bib0062
  article-title: Bisulfite Conversion of DNA from tissues, cell lines, buffy coat, FFPE tissues, microdissected cells, swabs, sputum, aspirates, lavages, effusions, plasma, serum, and urine
  publication-title: Methods Mol Biol
  contributor:
    fullname: Dietrich
– volume: 9
  start-page: 10918
  year: 2019
  ident: bib0071
  article-title: Tumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer
  publication-title: Sci Rep
  contributor:
    fullname: You
– volume: 8
  start-page: e000552
  year: 2020
  ident: bib0009
  article-title: LAG3 (LAG-3, CD223) DNA Methylation Correlates with LAG3 expression by tumor and immune Cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma.
  publication-title: J Immunother Cancer
  contributor:
    fullname: Bawden
– volume: 3
  year: 2018
  ident: bib0035
  article-title: CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients
  publication-title: JCI Insight
  contributor:
    fullname: Vogt
– volume: 7
  start-page: 13507
  year: 2016
  ident: bib0060
  article-title: Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease
  publication-title: Nat Commun
  contributor:
    fullname: Adams
– volume: 12
  start-page: 814
  year: 2017
  end-page: 823
  ident: bib0025
  article-title: LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes
  publication-title: J Thorac Oncol
  contributor:
    fullname: Rozeboom
– volume: 169
  start-page: 5392
  year: 2002
  end-page: 5395
  ident: bib0002
  article-title: Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3
  publication-title: J Immunol
  contributor:
    fullname: Vignali
– volume: 7
  start-page: 4509
  year: 2018
  end-page: 4516
  ident: bib0077
  article-title: Interferon gamma in cancer immunotherapy
  publication-title: Cancer Med
  contributor:
    fullname: Lu
– volume: 74
  start-page: 3418
  year: 2014
  end-page: 3428
  ident: bib0019
  article-title: LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses
  publication-title: Cancer Res
  contributor:
    fullname: Liu
– volume: 5
  year: 2016
  ident: bib0038
  article-title: Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
  publication-title: Oncoimmunology
  contributor:
    fullname: Dietrich
– volume: 15
  start-page: 101
  year: 2017
  ident: bib0057
  article-title: Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma
  publication-title: BMC Med
  contributor:
    fullname: Martinez-Cardus
– volume: 342
  start-page: 1432
  year: 2013
  end-page: 1433
  ident: bib0001
  article-title: Breakthrough of the year 2013
  publication-title: Cancer Immunother Sci
  contributor:
    fullname: Couzin-Frankel
– volume: 72
  start-page: 917
  year: 2012
  end-page: 927
  ident: bib0010
  article-title: Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape
  publication-title: Cancer Res
  contributor:
    fullname: Goldberg
– volume: 23
  start-page: 341
  year: 2018
  end-page: 351
  ident: bib0027
  article-title: Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-γ in peripheral blood
  publication-title: Cancer Biomark
  contributor:
    fullname: Keyoumu
– volume: 11
  start-page: 639
  year: 2019
  end-page: 653
  ident: bib0042
  article-title: Clinicopathological, immune and molecular correlates of PD-L2 methylation in gastric adenocarcinomas
  publication-title: Epigenomics
  contributor:
    fullname: Semaan
– volume: 8
  year: 2019
  ident: bib0055
  article-title: A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma
  publication-title: Elife
  contributor:
    fullname: Chen
– volume: 45
  start-page: 1148
  year: 2016
  end-page: 1161
  ident: bib0031
  article-title: Epigenomic profiling of human CD4+ T cells supports a linear differentiation model and highlights molecular regulators of memory development
  publication-title: Immunity
  contributor:
    fullname: Gasparoni
– volume: 24
  start-page: 3216
  issue: 12
  year: 1994
  ident: 10.1016/j.ebiom.2020.102962_bib0015
  article-title: Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes
  publication-title: Eur J Immunol
  doi: 10.1002/eji.1830241246
  contributor:
    fullname: Huard
– volume: 161
  start-page: 1681
  issue: 7
  year: 2015
  ident: 10.1016/j.ebiom.2020.102962_bib0049
  article-title: Genomic Classification of Cutaneous Melanoma
  publication-title: Cell
  doi: 10.1016/j.cell.2015.05.044
– volume: 9
  start-page: 1040
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0030
  article-title: Prognostic value of lymphocyte-activation Gene 3 (LAG3) in cancer: a meta-analysis
  publication-title: Front Oncol
  doi: 10.3389/fonc.2019.01040
  contributor:
    fullname: Saleh
– volume: 235
  start-page: 147
  issue: 1
  year: 2006
  ident: 10.1016/j.ebiom.2020.102962_bib0028
  article-title: A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2005.04.015
  contributor:
    fullname: Triebel
– volume: 30
  start-page: 413
  issue: 5
  year: 2012
  ident: 10.1016/j.ebiom.2020.102962_bib0050
  article-title: Absolute quantification of somatic DNA alterations in human cancer
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.2203
  contributor:
    fullname: Carter
– volume: 1589
  start-page: 139
  year: 2017
  ident: 10.1016/j.ebiom.2020.102962_bib0062
  article-title: Bisulfite Conversion of DNA from tissues, cell lines, buffy coat, FFPE tissues, microdissected cells, swabs, sputum, aspirates, lavages, effusions, plasma, serum, and urine
  publication-title: Methods Mol Biol
  doi: 10.1007/7651_2015_260
  contributor:
    fullname: Jung
– volume: 26
  start-page: 494
  issue: 2
  year: 2007
  ident: 10.1016/j.ebiom.2020.102962_bib0086
  article-title: Metalloproteases regulate T-cell proliferation and effector function via LAG-3
  publication-title: EMBO J
  doi: 10.1038/sj.emboj.7601520
  contributor:
    fullname: Li
– volume: 32
  start-page: 435
  issue: 3
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0043
  article-title: PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival
  publication-title: Pigment Cell Melanoma Res
  doi: 10.1111/pcmr.12745
  contributor:
    fullname: Micevic
– volume: 32
  start-page: 2255
  issue: 8
  year: 2002
  ident: 10.1016/j.ebiom.2020.102962_bib0005
  article-title: Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)
  publication-title: Eur J Immunol.
  doi: 10.1002/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A
  contributor:
    fullname: Workman
– volume: 6
  start-page: 27
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0072
  article-title: Immune cell infiltration of the primary tumor, Not PD-L1 status, is associated with improved response to checkpoint inhibition in metastatic melanoma
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2019.00027
  contributor:
    fullname: Kümpers
– volume: 182
  start-page: 6659
  issue: 11
  year: 2009
  ident: 10.1016/j.ebiom.2020.102962_bib0014
  article-title: Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.0804211
  contributor:
    fullname: Grosso
– volume: 134
  start-page: 1893
  issue: 7
  year: 2014
  ident: 10.1016/j.ebiom.2020.102962_bib0069
  article-title: Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3
  publication-title: J Invest Dermatol
  doi: 10.1038/jid.2014.29
  contributor:
    fullname: Camisaschi
– volume: 8
  start-page: e000552
  issue: 1
  year: 2020
  ident: 10.1016/j.ebiom.2020.102962_bib0009
  article-title: LAG3 (LAG-3, CD223) DNA Methylation Correlates with LAG3 expression by tumor and immune Cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma.
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-000552
  contributor:
    fullname: Klümper
– volume: 5
  issue: 10
  year: 2016
  ident: 10.1016/j.ebiom.2020.102962_bib0038
  article-title: Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1221555
  contributor:
    fullname: Goltz
– volume: 10
  start-page: 942
  issue: 9
  year: 2004
  ident: 10.1016/j.ebiom.2020.102962_bib0078
  article-title: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
  publication-title: Nat Med
  doi: 10.1038/nm1093
  contributor:
    fullname: Curiel
– volume: 28
  start-page: 2977
  issue: 12
  year: 2017
  ident: 10.1016/j.ebiom.2020.102962_bib0022
  article-title: LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx557
  contributor:
    fullname: Burugu
– volume: 19
  start-page: 1415
  issue: 12
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0076
  article-title: LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
  publication-title: Nat Immunol
  doi: 10.1038/s41590-018-0217-9
  contributor:
    fullname: Maruhashi
– volume: 176
  start-page: 334
  issue: 1–2
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0003
  article-title: Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3
  publication-title: Cell
  doi: 10.1016/j.cell.2018.11.010
  contributor:
    fullname: Wang
– volume: 5
  issue: 11
  year: 2016
  ident: 10.1016/j.ebiom.2020.102962_bib0023
  article-title: LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1239005
  contributor:
    fullname: Deng
– volume: 46
  start-page: D754
  issue: D1
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0089
  article-title: Ensembl 2018
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx1098
  contributor:
    fullname: Zerbino
– volume: 342
  start-page: 1432
  issue: 6165
  year: 2013
  ident: 10.1016/j.ebiom.2020.102962_bib0001
  article-title: Breakthrough of the year 2013
  publication-title: Cancer Immunother Sci
  contributor:
    fullname: Couzin-Frankel
– volume: 8
  start-page: 41011
  issue: 25
  year: 2017
  ident: 10.1016/j.ebiom.2020.102962_bib0039
  article-title: PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.17354
  contributor:
    fullname: Goltz
– volume: 23
  start-page: 226
  issue: 1
  year: 2014
  ident: 10.1016/j.ebiom.2020.102962_bib0056
  article-title: Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddt420
  contributor:
    fullname: Marzese
– volume: 10
  start-page: 943
  issue: 10
  year: 2015
  ident: 10.1016/j.ebiom.2020.102962_bib0059
  article-title: Integrative analysis of methylome and transcriptome in human blood identifies extensive sex- and immune cell-specific differentially methylated regions
  publication-title: Epigenetics
  doi: 10.1080/15592294.2015.1084462
  contributor:
    fullname: Mamrut
– volume: 10
  start-page: 453
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0065
  article-title: Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.00453
  contributor:
    fullname: Khair
– volume: 12
  start-page: 323
  year: 2011
  ident: 10.1016/j.ebiom.2020.102962_bib0063
  article-title: RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
  publication-title: BMC Bioinformatics
  doi: 10.1186/1471-2105-12-323
  contributor:
    fullname: Li
– volume: 52
  start-page: 102647
  year: 2020
  ident: 10.1016/j.ebiom.2020.102962_bib0047
  article-title: Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2020.102647
  contributor:
    fullname: Fröhlich
– volume: 117
  start-page: 3383
  issue: 11
  year: 2007
  ident: 10.1016/j.ebiom.2020.102962_bib0013
  article-title: LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems
  publication-title: J Clin Invest
  doi: 10.1172/JCI31184
  contributor:
    fullname: Grosso
– volume: 10
  start-page: 1745
  issue: 7
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0082
  article-title: Circulating lymphocytes, PD-L1 expression on tumor-infiltrating lymphocytes, and survival of colorectal cancer patients with different mismatch repair gene status
  publication-title: J Cancer
  doi: 10.7150/jca.25187
  contributor:
    fullname: Kong
– volume: 21
  start-page: 3031
  issue: 13
  year: 2015
  ident: 10.1016/j.ebiom.2020.102962_bib0024
  article-title: Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-2926
  contributor:
    fullname: Giraldo
– volume: 7
  start-page: 13507
  year: 2016
  ident: 10.1016/j.ebiom.2020.102962_bib0060
  article-title: Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease
  publication-title: Nat Commun
  doi: 10.1038/ncomms13507
  contributor:
    fullname: Ventham
– volume: 20
  start-page: 5064
  issue: 19
  year: 2014
  ident: 10.1016/j.ebiom.2020.102962_bib0081
  article-title: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-3271
  contributor:
    fullname: Taube
– volume: 6
  issue: 3
  year: 2017
  ident: 10.1016/j.ebiom.2020.102962_bib0036
  article-title: The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1288329
  contributor:
    fullname: Chen
– volume: 6
  issue: 1
  year: 2016
  ident: 10.1016/j.ebiom.2020.102962_bib0040
  article-title: PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1257454
  contributor:
    fullname: Goltz
– volume: 171
  start-page: 1393
  issue: 5
  year: 1990
  ident: 10.1016/j.ebiom.2020.102962_bib0048
  article-title: LAG-3, a novel lymphocyte activation gene closely related to CD4
  publication-title: J Exp Med
  doi: 10.1084/jem.171.5.1393
  contributor:
    fullname: Triebel
– volume: 23
  start-page: 181
  issue: 1
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0051
  article-title: Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2018.03.086
  contributor:
    fullname: Saltz
– volume: 22
  start-page: 1856
  issue: 8
  year: 2016
  ident: 10.1016/j.ebiom.2020.102962_bib0011
  article-title: Reversing T-cell dysfunction and exhaustion in cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-1849
  contributor:
    fullname: Zarour
– volume: 186
  start-page: 5173
  issue: 9
  year: 2011
  ident: 10.1016/j.ebiom.2020.102962_bib0029
  article-title: MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1002050
  contributor:
    fullname: Hemon
– volume: 191
  start-page: 3419
  issue: 6
  year: 2013
  ident: 10.1016/j.ebiom.2020.102962_bib0033
  article-title: Global DNA methylation remodeling accompanies CD8 T cell effector function
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1301395
  contributor:
    fullname: Scharer
– volume: 11
  start-page: 587
  year: 2010
  ident: 10.1016/j.ebiom.2020.102962_bib0061
  article-title: Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis
  publication-title: BMC Bioinf
  doi: 10.1186/1471-2105-11-587
  contributor:
    fullname: Du
– volume: 16
  start-page: 275
  issue: 5
  year: 2016
  ident: 10.1016/j.ebiom.2020.102962_bib0073
  article-title: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2016.36
  contributor:
    fullname: Topalian
– volume: 7
  start-page: 264
  issue: 1
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0087
  article-title: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-019-0737-3
  contributor:
    fullname: Wu
– volume: 15
  start-page: 101
  issue: 1
  year: 2017
  ident: 10.1016/j.ebiom.2020.102962_bib0057
  article-title: Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma
  publication-title: BMC Med
  doi: 10.1186/s12916-017-0851-3
  contributor:
    fullname: Wouters
– volume: 137
  start-page: 1194
  issue: 7
  year: 2009
  ident: 10.1016/j.ebiom.2020.102962_bib0066
  article-title: CTCF: master weaver of the genome
  publication-title: Cell
  doi: 10.1016/j.cell.2009.06.001
  contributor:
    fullname: Phillips
– volume: 7
  start-page: 79943
  issue: 48
  year: 2016
  ident: 10.1016/j.ebiom.2020.102962_bib0037
  article-title: PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13161
  contributor:
    fullname: Gevensleben
– volume: 7
  issue: 3
  year: 2017
  ident: 10.1016/j.ebiom.2020.102962_bib0083
  article-title: Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1356144
  contributor:
    fullname: Xing
– volume: 170
  start-page: 142
  issue: 1
  year: 2017
  ident: 10.1016/j.ebiom.2020.102962_bib0032
  article-title: De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation
  publication-title: Cell
  doi: 10.1016/j.cell.2017.06.007
  contributor:
    fullname: Ghoneim
– volume: 31
  start-page: 738
  issue: 3
  year: 2017
  ident: 10.1016/j.ebiom.2020.102962_bib0041
  article-title: PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia
  publication-title: Leukemia
  doi: 10.1038/leu.2016.328
  contributor:
    fullname: Goltz
– volume: 12
  start-page: 453
  issue: 5
  year: 2015
  ident: 10.1016/j.ebiom.2020.102962_bib0053
  article-title: Robust enumeration of cell subsets from tissue expression profiles
  publication-title: Nat Methods
  doi: 10.1038/nmeth.3337
  contributor:
    fullname: Newman
– volume: 5
  start-page: 13351
  year: 2015
  ident: 10.1016/j.ebiom.2020.102962_bib0068
  article-title: Integrated transcriptomics establish macrophage polarization signatures and have potential applications for clinical health and disease
  publication-title: Sci Rep
  doi: 10.1038/srep13351
  contributor:
    fullname: Becker
– volume: 276
  start-page: 80
  issue: 1
  year: 2017
  ident: 10.1016/j.ebiom.2020.102962_bib0006
  article-title: LAG3 (CD223) as a cancer immunotherapy target
  publication-title: Immunol Rev
  doi: 10.1111/imr.12519
  contributor:
    fullname: Andrews
– volume: 28
  start-page: 97
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0044
  article-title: PD-1 (PDCD1) promoter methylation is a prognostic factor in patients with diffuse lower-grade gliomas harboring isocitrate dehydrogenase (IDH) mutations
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2018.01.016
  contributor:
    fullname: Röver
– volume: 169
  start-page: 5392
  issue: 10
  year: 2002
  ident: 10.1016/j.ebiom.2020.102962_bib0002
  article-title: Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3
  publication-title: J Immunol
  doi: 10.4049/jimmunol.169.10.5392
  contributor:
    fullname: Workman
– volume: 182
  start-page: 1885
  issue: 4
  year: 2009
  ident: 10.1016/j.ebiom.2020.102962_bib0004
  article-title: LAG-3 regulates plasmacytoid dendritic cell homeostasis
  publication-title: J Immunol
  doi: 10.4049/jimmunol.0800185
  contributor:
    fullname: Workman
– volume: 11
  start-page: 639
  issue: 6
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0042
  article-title: Clinicopathological, immune and molecular correlates of PD-L2 methylation in gastric adenocarcinomas
  publication-title: Epigenomics
  doi: 10.2217/epi-2018-0149
  contributor:
    fullname: Lingohr
– volume: 3
  start-page: 412
  issue: 4
  year: 2015
  ident: 10.1016/j.ebiom.2020.102962_bib0018
  article-title: Galectin-3 shapes antitumor immune responses by suppressing CD8+ T Cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-14-0150
  contributor:
    fullname: Kouo
– volume: 107
  start-page: 1193
  issue: 9
  year: 2016
  ident: 10.1016/j.ebiom.2020.102962_bib0064
  article-title: Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
  publication-title: Cancer Sci
  doi: 10.1111/cas.12986
  contributor:
    fullname: He
– volume: 48
  start-page: 812
  issue: 4
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0052
  article-title: The immune landscape of cancer
  publication-title: Immunity
  doi: 10.1016/j.immuni.2018.03.023
  contributor:
    fullname: Thorsson
– volume: 4
  start-page: 38
  issue: 1
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0079
  article-title: Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive ‘Cold’ Tumors ‘Hot’
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2017.11.005
  contributor:
    fullname: Prendergast
– volume: 9
  issue: 8
  year: 2013
  ident: 10.1016/j.ebiom.2020.102962_bib0058
  article-title: Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations
  publication-title: PLoS Genet
  doi: 10.1371/journal.pgen.1003678
  contributor:
    fullname: Absher
– volume: 7
  start-page: 4509
  issue: 9
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0077
  article-title: Interferon gamma in cancer immunotherapy
  publication-title: Cancer Med
  doi: 10.1002/cam4.1700
  contributor:
    fullname: Ni
– volume: 11
  start-page: 1213
  issue: 8
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0075
  article-title: LAG3: the biological processes that motivate targeting this immune checkpoint molecule in human cancer
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11081213
  contributor:
    fullname: Solinas
– volume: 22
  start-page: 13
  issue: 1
  year: 2010
  ident: 10.1016/j.ebiom.2020.102962_bib0067
  article-title: On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection
  publication-title: Int Immunol
  doi: 10.1093/intimm/dxp107
  contributor:
    fullname: Richter
– volume: 64
  start-page: 853
  issue: 7
  year: 2015
  ident: 10.1016/j.ebiom.2020.102962_bib0084
  article-title: Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-015-1696-2
  contributor:
    fullname: Yu
– volume: 72
  start-page: 917
  issue: 4
  year: 2012
  ident: 10.1016/j.ebiom.2020.102962_bib0010
  article-title: Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-1620
  contributor:
    fullname: Woo
– volume: 74
  start-page: 3418
  issue: 13
  year: 2014
  ident: 10.1016/j.ebiom.2020.102962_bib0019
  article-title: LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-2690
  contributor:
    fullname: Xu
– volume: 23
  start-page: 341
  issue: 3
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0027
  article-title: Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-γ in peripheral blood
  publication-title: Cancer Biomark
  doi: 10.3233/CBM-181278
  contributor:
    fullname: Li
– volume: 111
  start-page: 1391
  issue: 7
  year: 2014
  ident: 10.1016/j.ebiom.2020.102962_bib0074
  article-title: PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2014.416
  contributor:
    fullname: Wu
– volume: 21
  start-page: 503
  issue: 4
  year: 2004
  ident: 10.1016/j.ebiom.2020.102962_bib0007
  article-title: Role of LAG-3 in regulatory T cells
  publication-title: Immunity
  doi: 10.1016/j.immuni.2004.08.010
  contributor:
    fullname: Huang
– volume: 32
  start-page: 412
  issue: 3
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0054
  article-title: Comparison of five different scoring methods in the evaluation of inflammatory infiltration (tumor-infiltrating lymphocytes) in superficial spreading and nodular melanoma
  publication-title: Pigment Cell Melanoma Res
  doi: 10.1111/pcmr.12757
  contributor:
    fullname: Němejcová
– volume: 9
  start-page: 51
  year: 2017
  ident: 10.1016/j.ebiom.2020.102962_bib0034
  article-title: Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
  publication-title: Clin Epigenetics
  doi: 10.1186/s13148-017-0354-2
  contributor:
    fullname: Marwitz
– volume: 184
  start-page: 6545
  issue: 11
  year: 2010
  ident: 10.1016/j.ebiom.2020.102962_bib0008
  article-title: LAG-3 Expression Defines a Subset of CD4 + CD25 high Foxp3 + Regulatory T Cells That Are Expanded at Tumor Sites
  publication-title: J Immunol
  doi: 10.4049/jimmunol.0903879
  contributor:
    fullname: Camisaschi
– volume: 172
  start-page: 5450
  issue: 9
  year: 2004
  ident: 10.1016/j.ebiom.2020.102962_bib0017
  article-title: Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo
  publication-title: J Immunol
  doi: 10.4049/jimmunol.172.9.5450
  contributor:
    fullname: Workman
– volume: 11
  start-page: e6352
  issue: 12
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0070
  article-title: PD-L1, PD-1, LAG-3, and TIM-3 in melanoma: expression in brain metastases compared to corresponding extracranial tumors
  publication-title: Cureus
  contributor:
    fullname: Wang
– volume: 9
  issue: 11
  year: 2014
  ident: 10.1016/j.ebiom.2020.102962_bib0012
  article-title: Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0109080
  contributor:
    fullname: Durham
– volume: 9
  issue: 8
  year: 2014
  ident: 10.1016/j.ebiom.2020.102962_bib0020
  article-title: Lymphocyte activation Gene-3 (LAG-3) negatively regulates environmentally-induced autoimmunity
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0104484
  contributor:
    fullname: Jha
– volume: 8
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0055
  article-title: A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma
  publication-title: Elife
  doi: 10.7554/eLife.44310
  contributor:
    fullname: Guo
– volume: 144
  start-page: 1005
  issue: 6
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0026
  article-title: CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-018-2620-x
  contributor:
    fullname: Lee
– volume: 127
  start-page: 2930
  issue: 8
  year: 2017
  ident: 10.1016/j.ebiom.2020.102962_bib0088
  article-title: IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
  publication-title: J Clin Invest
  doi: 10.1172/JCI91190
  contributor:
    fullname: Ayers
– volume: 193
  start-page: 3101
  issue: 6
  year: 2014
  ident: 10.1016/j.ebiom.2020.102962_bib0021
  article-title: Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1401025
  contributor:
    fullname: Bae
– volume: 12
  start-page: 814
  issue: 5
  year: 2017
  ident: 10.1016/j.ebiom.2020.102962_bib0025
  article-title: LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2017.01.019
  contributor:
    fullname: He
– volume: 3
  issue: 13
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0035
  article-title: CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.96793
  contributor:
    fullname: Goltz
– volume: 6
  start-page: 623
  issue: 5
  year: 2011
  ident: 10.1016/j.ebiom.2020.102962_bib0085
  article-title: Significant differences in global genomic DNA methylation by gender and race/ethnicity in peripheral blood
  publication-title: Epigenetics
  doi: 10.4161/epi.6.5.15335
  contributor:
    fullname: Zhang
– volume: 12
  start-page: 198
  issue: 3
  year: 2002
  ident: 10.1016/j.ebiom.2020.102962_bib0016
  article-title: Do the molecules CD26 and lymphocytes activation gene-3 differentiate between type 1 and 2 T cell response?
  publication-title: J Investig Allergol Clin Immunol.
  contributor:
    fullname: Rogala
– volume: 45
  start-page: 1148
  issue: 5
  year: 2016
  ident: 10.1016/j.ebiom.2020.102962_bib0031
  article-title: Epigenomic profiling of human CD4+ T cells supports a linear differentiation model and highlights molecular regulators of memory development
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.10.022
  contributor:
    fullname: Durek
– volume: 119
  start-page: 950
  issue: 8
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0080
  article-title: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
  publication-title: Br J Cancer
  doi: 10.1038/s41416-018-0220-9
  contributor:
    fullname: Fumet
– volume: 8
  issue: 2
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0045
  article-title: DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1542918
  contributor:
    fullname: Elashi
– volume: 10
  start-page: 78
  year: 2018
  ident: 10.1016/j.ebiom.2020.102962_bib0046
  article-title: DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
  publication-title: Clin Epigenetics
  doi: 10.1186/s13148-018-0512-1
  contributor:
    fullname: Nair
– volume: 9
  start-page: 10918
  issue: 1
  year: 2019
  ident: 10.1016/j.ebiom.2020.102962_bib0071
  article-title: Tumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-47382-3
  contributor:
    fullname: Xiong
SSID ssj0001542358
Score 2.3815207
Snippet The co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a potential target for immune checkpoint inhibition immunotherapies. However, little is...
BACKGROUNDThe co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a potential target for immune checkpoint inhibition immunotherapies. However,...
Background: The co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a potential target for immune checkpoint inhibition immunotherapies. However,...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 102962
SubjectTerms DNA Methylation
Immunotherapy
LAG3
Melanoma
Predictive Biomarker
Research paper
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaqSkhcKiivAK2MxHEj4viVHBdoqRDtqZV6s2yPLRaVpCrbQ_89Y3tTbagEF455KLszY2e-T5n5hpD3rpeOdxGZqgdb406E2nFta6ZD39joQfepG_n0TJ1ciK-X8nJr1FeqCSvywMVxH0IDkUUNMeooANNr4yN0njkFWoS-qJc2_RaZKv3BIvWA5slysq15r8QkOZSLu0Jqbkd22Gbtgl61s7SU1ftn2ekh-vyziHIrKx0_IXsbOEmXxYynZCcM--RRGTB594y402n67YKWHsgxjSCeXngLagegq9QiEqhPczquEvSkY6Tfll84vc61euGGfj5b0jRr-q5UztHVgIdXdhh_2ufk4vjo_NNJvZmqUHvZynUdISipbRCSIUFtAjIk5Cwd4ibnWw5MQHSAmV02QTkhhWskSBak90rpBiR_QXaHcQivCPWRSYuExOrIBQAyD8Ej-pu3LijfhYosJqea6yKeYaaqsh8mx8CkGJgSg4p8TI6_vzUpX-cTuB7MZj2Yf62HiqgpbGYDIgo4wEet_v7r76YgG9xi6buJHcJ4-8u0gidZQkRGFXlZgn7_H3nbKcb6riJ6thxmRsyvDKvvWcYbiRyiXfb6f1j9hjxOppTit7dkd31zGw4QLa3dYd4YvwHCKRPn
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLaqIlAviJ2URUbiOEFxvCUHhIalVIj2xEi9WV7poCFpp1OJ-fc8x3EhUHHgmMWJ4_ee3_cpb0HopWm5oU0ApmqdLsESXWmo1CWRvq10sE62MRv56FgcLtinE36yg3JX1HEBL66ldrGf1GK9evXjfPsGDP71r1gtH3PVgezVQymCNu7JN2oGVD3G8o14P6UNs5gamqsPXT92D92idSMI0PGJsxpq-k981t-Y9M_Qyt981cEddHsEmXietOIu2vHdPXQztZ3c3kfmKPfEneGUGdnHxsR5G5xh3Tm8jIkjHtvYvWMVASnuA_48_0jx2RDB59f4_fEcxw7U2xRPh5cdHK5013_XD9Di4MOXd4fl2GuhtLzmmzI4L7jUnnECtLXywJuAyTSApoytqSPMBePA3_PKC8M4MxV3nHhurRCycpw-RLtd3_nHCNtAuAaaomWgzDngI4wGwHm0Nl7YxhdolhdVnaWSGirHmn1TgzhUFIdK4ijQ27jwV7fGetjDiX79VY3mpXzlAgnShSADcwDCKhtcY4kRTjLf8gKJLDY1QosEGeBRy3-__UUWsgLDi39TdOf7ywsF-hWLFQJeKtCjJPSrOWb9KZCcqMPkI6ZXuuXpUNwb6B1gYLL_3yOfoL04_xQH9xTtbtaX_hkAp415PhjDTx7NGWY
  priority: 102
  providerName: Scholars Portal
Title Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
URI https://dx.doi.org/10.1016/j.ebiom.2020.102962
https://www.ncbi.nlm.nih.gov/pubmed/32861198
https://search.proquest.com/docview/2438679129
https://pubmed.ncbi.nlm.nih.gov/PMC7475111
https://doaj.org/article/e0df1f7dff7f4d3890cfd8c1b6d74e95
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaSkhcEG_CS0biuGmT-JU9LoVSAVuBRKXeLD9L0G6yWraH_nvGdlw1IHHgYilvJzOOvy_5Zgaht3rONGk9MFVjVQkj0ZaaCFXWws0r5Y0V8xCNvDzjp-f00wW72EMsx8JE0b7R3WG_Wh_23Y-ordyszVHWiR19XR4DBGZBjrOP9sFBb1H0FBpMQ_hnzjAUtVwuxLIDGWxiqoI5DzVsSNPyGij3ZEKKefsn89LfuPNP-eSt-ejkPro3Akm8SB1-gPZc_xDdSaUlrx8hvcx1b2c4RT8OofhwftXNsOot7kJwiMMmVOhYBdCJB4-_LD4SvIkqPbfF788WOFSZvk6aOdz1sLhS_bBWj9H5yYfvx6flWE-hNKxhu9Jbx5lQjrIaqGnlgBsBW2kBMWnTEFtT67WFOZ1VjmvKqK6YZbVjxnAuKsvIE3TQD717hrDxNVNARZTwhFoLnIMSD1iONNpx07oCzfJDlZuUNkNmPdlPGc0hgzlkMkeB3oUHf7NryHkdVwzbSzlaXrrK-toL673w1ALQqoy3rak1t4K6OSsQz2aTI3xIsABO1f376m-ykSUMrvDHRPVuuPolG0pCQkLARAV6mox-08fsPwUSE3eY3MR0C_hzTOA9-u_z_z7yBbob-p-0bi_RwW575V4BONrp1_GjArSfv7XQLmloYXj8BnlvE3I
link.rule.ids 230,315,730,783,787,867,888,2109,24330,27936,27937,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaWRQguvBfC00gcm24S23FyLAtLgbbisIv2ZsUvCLRJVdrD8usZx_Fqs0hIcEyc12TG8fcp38wg9FqWTJLCAlNVuophJupYEl7FKTdlUlmleemykeeLfHpKP56xsz3EQi5MJ9pXsh43y9W4qb912sr1Sh0Gndjh5_kRQGDm5DjX0HWYrwm9RNJ9cjB1CaChxlCn5jIumx3oYNYVKyhz18WGZEWeAukeLEld5f7ByvQn8rwqoLy0Ih3fQV-CLV6I8mO828qx-nWlzOM_G3sX3e4xKp744XtozzT30Q3ftfL8AZLz0FJ3hH1iZev6Goev6AhXjca1yzsxWLnmH0uHZ3Fr8WzynuB1JwA0G_x2McGugfW5l-PhuoHNZdW0q-ohOj1-d3I0jftWDbFiGdvGVpuc8cpQlgLrTQzQLiBCBYAxqTKiU6qt1AAXWGJySRmVCdMsNUypPOeJZuQA7TdtYx4jrGzKKmA5FbeEag10hhILMJFk0uSqMBEaBW-Jta_IIYJU7bvo_Cycn4X3c4TeOI9eHOrKaXc72s1X0b9nYRJtU8u1tdxSDRguUVYXKpW55tSULEJ5iAfRIxOPOOBS9d_v_ipEj4B5637GVI1pdz9FRomrdQhwK0KPfDRdPGMIzAjxQZwNjBiOQPR0tcH7aHny32e-RDenJ_OZmH1YfHqKbjlbvKTuGdrfbnbmOWCwrXzRzbjf9Acyng
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BEYhLeZaa5yJxjBPb-7B9DC2hQBP1QKWKy8r7gkBiRyE5lF_P7K5dxUXi0KPt9WM8s97vk7-ZQeidLJkkhQWmqnQVw0zUsSR5Fae5KZPKKp2XLht5OuMn5_TzBbvYafXlRftKzof1Yjms5z-8tnK1VKNOJzY6mx4BBGZOjrPSdnQb3YE5m_Adoh4ShKlLAu3qDHlFl3EZ7UAJM1-woOSukw3JCp4C8e4tS756f291-hd9XhdR7qxKkwfoW2dPEKP8Gm43cqj-XCv1eCODH6L9FqvicRjyCN0y9WN0N3SvvHyC5LRrrTvAIcGycf2Nu6_pAFe1xnOXf2Kwck1AFg7X4sbi0_FHgldeCGjW-Hg2xq6R9WWQ5eF5DZuLqm6W1VN0Pvnw9egkbls2xIplbBNbbTjLK0NZCuw3MUC_gBAVAMqkyohOqbZSA2xgieGSMioTpllqmFKc54lm5ADt1U1tDhFWNmUVsJ0qt4RqDbSGEgtwkWTScFWYCA06j4lVqMwhOsnaT-F9LZyvRfB1hN47r14NdWW1_Y5m_V2071qYRNvU5tra3FINWC5RVhcqlVzn1JQsQryLCdEilIA84FLz_9_9bRdBAuav-ylT1abZ_hYZJa7mIcCuCD0LEXX1jF1wRijvxVrPiP4RiCBfI7yNmOc3PvMNund2PBGnn2ZfXqD7zpSgrHuJ9jbrrXkFUGwjX_tJ9xd48zUe
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular%2C+clinicopathological%2C+and+immune+correlates+of+LAG3+promoter+DNA+methylation+in+melanoma&rft.jtitle=EBioMedicine&rft.au=Fr%C3%B6hlich%2C+Anne&rft.au=Sirokay%2C+Judith&rft.au=Fietz%2C+Simon&rft.au=Vogt%2C+Timo+J.&rft.date=2020-09-01&rft.pub=Elsevier&rft.eissn=2352-3964&rft.volume=59&rft_id=info:doi/10.1016%2Fj.ebiom.2020.102962&rft_id=info%3Apmid%2F32861198&rft.externalDBID=PMC7475111
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2352-3964&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2352-3964&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2352-3964&client=summon